Literature DB >> 18975976

Structural interactions in chondroitin 4-sulfate mediated adherence of Plasmodium falciparum infected erythrocytes in human placenta during pregnancy-associated malaria.

Rajeshwara N Achur1, Ikuko Kakizaki, Suchi Goel, Kaoru Kojima, SubbaRao V Madhunapantula, Atul Goyal, Misato Ohta, Sanjeev Kumar, Keiichi Takagaki, D Channe Gowda.   

Abstract

Infection with Plasmodium falciparum during pregnancy results in the adherence of infected red blood cells (IRBCs) in placenta, causing pregnancy-associated malaria with severe health complications in mothers and fetuses. The chondroitin 4-sulfate (C4S) chains of very low sulfated chondroitin sulfate proteoglycans (CSPGs) in placenta mediate the IRBC adherence. While it is known that partially sulfated but not fully sulfated C4S effectively binds IRBCs, structural interactions involved remain unclear and are incompletely understood. In this study, structurally defined C4S oligosaccharides of varying sulfate contents and sizes were evaluated for their ability to inhibit the binding of IRBCs from different P. falciparum strains to CSPG purified from placenta. The results clearly show that, with all parasite strains studied, dodecasaccharide is the minimal chain length required for the efficient adherence of IRBCs to CSPG and two 4-sulfated disaccharides within this minimal structural motif are sufficient for maximal binding. Together, these data demonstrate for the first time that the C4S structural requirement for IRBC adherence is parasite strain-independent. We also show that the carboxyl group on nonreducing end glucuronic acid in dodecasaccharide motif is important for IRBC binding. Thus, in oligosaccharides containing terminal 4,5-unsaturated glucuronic acid, the nonreducing end disaccharide moiety does not interact with IRBCs due to the altered spatial orientation of carboxyl group. In such C4S oligosaccharides, 14-mer but not 12-mer constitutes the minimal motif for inhibition of IRBC binding to placental CSPG. These data have important implications for the development and evaluation of therapeutics and vaccine for placental malaria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18975976      PMCID: PMC2645940          DOI: 10.1021/bi801643m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  37 in total

1.  Calcium chondroitin 4-sulfate: molecular conformation and organization of polysaccharide chains in a proteoglycan.

Authors:  J J Cael; W T Winter; S Arnott
Journal:  J Mol Biol       Date:  1978-10-15       Impact factor: 5.469

Review 2.  Molecular aspects of severe malaria.

Authors:  Q Chen; M Schlichtherle; M Wahlgren
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

3.  Enzymatic reconstruction of a hybrid glycosaminoglycan containing 6-sulfated, 4-sulfated, and unsulfated N-acetylgalactosamine.

Authors:  K Takagaki; H Munakata; M Majima; M Endo
Journal:  Biochem Biophys Res Commun       Date:  1999-05-19       Impact factor: 3.575

4.  Structural basis for the adherence of Plasmodium falciparum-infected erythrocytes to chondroitin 4-sulfate and design of novel photoactivable reagents for the identification of parasite adhesive proteins.

Authors:  A S Prakasha Gowda; SubbaRao V Madhunapantula; Rajeshwara N Achur; Manojkumar Valiyaveettil; Veer P Bhavanandan; D Channe Gowda
Journal:  J Biol Chem       Date:  2006-11-03       Impact factor: 5.157

5.  Preparation and structural determination of dermatan sulfate-derived oligosaccharides.

Authors:  H O Yang; N S Gunay; T Toida; B Kuberan; G Yu; Y S Kim; R J Linhardt
Journal:  Glycobiology       Date:  2000-10       Impact factor: 4.313

Review 6.  Malaria and the red cell.

Authors:  David J Weatherall; Louis H Miller; Dror I Baruch; Kevin Marsh; Ogobara K Doumbo; Climent Casals-Pascual; David J Roberts
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002

Review 7.  Plasmodium falciparum adhesion in the placenta.

Authors:  Patrick E Duffy; Michal Fried
Journal:  Curr Opin Microbiol       Date:  2003-08       Impact factor: 7.934

8.  Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight.

Authors:  I A McGregor; M E Wilson; W Z Billewicz
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

9.  Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA.

Authors:  Marion Avril; Bridget R Kulasekara; Severin O Gose; Chris Rowe; Madeleine Dahlbäck; Patrick E Duffy; Michal Fried; Ali Salanti; Lynda Misher; David L Narum; Joseph D Smith
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

10.  Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA.

Authors:  Pernille Andersen; Morten A Nielsen; Mafalda Resende; Thomas S Rask; Madeleine Dahlbäck; Thor Theander; Ole Lund; Ali Salanti
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

View more
  12 in total

1.  Targeted disruption of a ring-infected erythrocyte surface antigen (RESA)-like export protein gene in Plasmodium falciparum confers stable chondroitin 4-sulfate cytoadherence capacity.

Authors:  Suchi Goel; Arivalagan Muthusamy; Jun Miao; Liwang Cui; Ali Salanti; Elizabeth A Winzeler; D Channe Gowda
Journal:  J Biol Chem       Date:  2014-10-23       Impact factor: 5.157

2.  Exploiting enzyme specificities in digestions of chondroitin sulfates A and C: production of well-defined hexasaccharides.

Authors:  Vitor H Pomin; Younghee Park; Rongrong Huang; Christian Heiss; Joshua S Sharp; Parastoo Azadi; James H Prestegard
Journal:  Glycobiology       Date:  2012-02-17       Impact factor: 4.313

3.  Proteomic analysis of potential keratan sulfate, chondroitin sulfate A, and hyaluronic acid molecular interactions.

Authors:  Abigail H Conrad; Yuntao Zhang; Elena S Tasheva; Gary W Conrad
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

4.  Characterization of human placental glycosaminoglycans and regional binding to VAR2CSA in malaria infected erythrocytes.

Authors:  Julie M Beaudet; Leandra Mansur; Eun Ji Joo; Eyal Kamhi; Bo Yang; Thomas M Clausen; Ali Salanti; Fuming Zhang; Robert J Linhardt
Journal:  Glycoconj J       Date:  2013-10-25       Impact factor: 2.916

5.  Discovery of a Small-Molecule Modulator of Glycosaminoglycan Sulfation.

Authors:  Sheldon T Cheung; Michelle S Miller; Reynand Pacoma; Jason Roland; Jian Liu; Andrew M Schumacher; Linda C Hsieh-Wilson
Journal:  ACS Chem Biol       Date:  2017-11-29       Impact factor: 5.100

6.  Plasmodium falciparum: Assessment of parasite-infected red blood cell binding to placental chondroitin proteoglycan and bovine tracheal chondroitin sulfate A.

Authors:  Atul Goyal; Suchi Goel; D Channe Gowda
Journal:  Exp Parasitol       Date:  2009-06-07       Impact factor: 2.011

7.  An affinity chromatography and glycoproteomics workflow to profile the chondroitin sulfate proteoglycans that interact with malarial VAR2CSA in the placenta and in cancer.

Authors:  Alejandro Gómez Toledo; Jessica Pihl; Charlotte B Spliid; Andrea Persson; Jonas Nilsson; Marina Ayres Pereira; Tobias Gustavsson; Swati Choudhary; Htoo Zarni Oo; Peter C Black; Mads Daugaard; Jeffrey D Esko; Göran Larson; Ali Salanti; Thomas Mandel Clausen
Journal:  Glycobiology       Date:  2020-12-09       Impact factor: 4.313

8.  How specific is Plasmodium falciparum adherence to chondroitin 4-sulfate?

Authors:  Suchi Goel; D Channe Gowda
Journal:  Trends Parasitol       Date:  2011-04-18

Review 9.  Bioengineered 3D Microvessels for Investigating Plasmodium falciparum Pathogenesis.

Authors:  Maria Bernabeu; Caitlin Howard; Ying Zheng; Joseph D Smith
Journal:  Trends Parasitol       Date:  2021-01-20

Review 10.  Synthesis of neoproteoglycans using the transglycosylation reaction as a reverse reaction of endo-glycosidases.

Authors:  Masahiko Endo; Ikuko Kakizaki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.